%0 Journal Article
%T Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores
%A Bengt Glimelius
%A Daniel Dietrich
%A Gy£¿rgy Bodoky
%A Peter Brauchli
%A Piera Gargiulo
%A Richard Herrmann
%A Sandro Pignata
%A Simona Berardi
%A Thomas Ruhstaller
%A Werner Scheithauer
%J Archive of "Therapeutic Advances in Medical Oncology".
%D 2019
%R 10.1177/1758835918818351
%X The prognosis of advanced pancreatic cancer (APC) is poor and differs considerably among patients. Therefore, it is clinically relevant to identify patients with APC who are more likely to benefit from palliative chemotherapy with reduced risk of toxicity. To date, there is no prognostic score universally recommended to help clinicians in planning the therapeutic management
%K advanced pancreatic cancer
%K chemotherapy
%K inflammatory markers
%K mortality
%K prediction score
%K toxicity
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6317152/